


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop: Amendments, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on this 10th day of December 2004.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Mark E. SCHNUTE et al.

Group Art Unit: 1625

Serial No.: 10/649,301

Examiner: Evelyn Huang

Filed: August 27, 2003

Confirmation No.: 5396

For: Heteroaryl-ethanolamine Derivatives
as Antiviral Agents

Mail Stop: Amendment
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

1. Transmittal Letter (one page)
2. Amendment (11 pages)
3. Copy of Amendments to the Claims Marked Up to Show the Changes Therein (one page)
4. Copy of Office Action mailed November 30, 2004 (2 pages)
4. Postcard

Respectfully submitted,

Date: December 10, 2004



Karl O. Neiderf
Attorney For Applicant
Registration No. 39,313

Agouron Pharmaceuticals, Inc.
A Pfizer Company
Legal Division, Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: 858/622-8060
Fax: 858/678-8233

Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to: Amendment,
Commissioner for Patents, PO Box 1450, Alexandria,
VA 22313-1450 on this 10th day of December 2004.

PC27589A(1206)
Amendment

[PW]



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Mark E. SCHNUTE et al.

Group Art Unit: 1625

Serial No.: 10/649,301

Examiner: Evelyn Huang

Confirmation No.: 5396

Filed: August 27, 2003

For: Heteroaryl-ethanolamine Derivatives
as Antiviral Agents

Mail Stop: Amendment
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

Responsive to the Notice of Non-Compliant Amendment (37 CFR 1.121) mailed November 30, 2004, please amend the claims as follows:

- Amendments to the Specification begin on page ___ of this paper.
- Amendments to the Claims are reflected in the listing of claims, which begins on page 3 of this paper.
- Amendments to the Drawings begin on page ___ of this paper and include both an attached replacement sheet and an annotated sheet showing changes.
- Remarks begin on page 11 of this paper.